Celebrex returns to TV with long, blunt spot

Share this article:
Pfizer resumed DTC television advertising for Celebrex on Monday with a whopping 150-second spot that takes up an entire commercial break. Turning conventions of traditional prescription drug TV spots upside down, the spot, created by Kaplan Thaler, presents its warning information first – noting that Celebrex, and rivals ibuprofen and naproxen, all may cause heart attack, stroke and death. Celebrex’s benefits are stated afterward. The two-and-a-half-minute Celebrex spot uses blue and white lines composed of words from the package inserts of Pfizer painkiller and other drugs to create animations of people running, dancing and riding a bicycle. Pfizer spokesman Jack Cox told MM&M the ad will appear on network and cable television with a print complement to appear in national publications such as Time and US News and World Report. The ad also appears on the product’s Web site at Celebrex.com. Each commercial may cost more than $200,000 to air. Pfizer yanked television advertising for Celebrex in the wake of the 2004 withdrawal of Merck’s Vioxx. An FDA panel later said that painkillers similar to Vioxx, known as COX- 2 inhibitors, also carried the same risks of heart attack and stroke. As a result, Pfizer withdrew its COX-2 Bextra from the market in April 2005. Celebrex, however, remains available to consumers. Even without a major TV ad campaign behind the brand, global sales of Celebrex jumped 18% in 2006, exceeding $2 billion.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...